At the 12th Chinese Society for Colposcopy and Cervical Pathology (CSCCP) Meeting, PHASE Scientific (PHASE) presented an integrated cervical cancer prevention pathway designed to support screening, diagnosis, and treatment through a combination of molecular testing and medical devices. The company highlighted how a single, non-invasive urine sample can be used not only for primary HPV screening, but also, where appropriate, for molecular triage, helping connect early detection with timely clinical action.
Interim evaluation findings from the “Establishment and Promotion of an Innovative Model for Cervical Cancer Prevention and Control (SCOCCAPS)” study were shared by Peking University Shenzhen Hospital (PUSH) and collaborating clinical institutions during the Meeting. As the study’s technology partner, PHASE emphasised a closed-loop workflow built around its patented PHASiFY sample preparation technology, which is designed to increase the concentration of target analytes in liquid samples such as urine. The overall model aims to reduce practical barriers—such as limited access to sampling, repeat visits for additional testing, and delays in referral—especially in primary-care and resource-limited settings.
The pathway begins with PHASiFY-enabled urine HPV testing for primary screening. For individuals who test HPV-positive, the same workflow can trigger host methylation testing as a triage step to support risk stratification and help guide next steps, such as colposcopy and subsequent clinical management. PHASE presented this “one urine, two tests” approach as a practical model that could be scaled to help more women complete the screening-to-management continuum.
China has continued expanding its “two-cancer screening” initiatives, yet cervical cancer screening coverage among eligible women in 2023–2024 was 51.5 per cent overall and 48.2 per cent in rural areas—still short of the World Health Organisation’s 70 per cent target. PHASE noted that evidence-backed, easier-to-access screening pathways could help reduce the gap for women who have never been screened, while supporting primary-level institutions in delivering a more complete prevention-and-control continuum in line with China’s Accelerating Cervical Cancer Elimination Action Plan (2023–2030).
Dr. Ricky Chiu, Founder and CEO of PHASE, said: “Meeting cervical cancer prevention and control goals will take more than any one test or product. What’s needed is an integrated, end-to-end pathway—from screening to diagnosis to treatment—designed for the realities of primary-care settings. That’s the intention behind PHASE’s full-scope solution.”
